British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay ...

The agreement announced Wednesday brings GSK efimosfermin alfa, a Boston Pharmaceuticals drug that is ready for Phase 3 testing. In addition to metabolic dysfunction-associated steatohepatitis ...

GSK plc GSK on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Under the agreement, GSK will pay up to $2 billion in total cash consideration. This includes $1 ...

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) · Affecting up to 5% of the global ...

The deal for efimosfermin, which GSK described as ready for Phase 3 studies, includes another $800 million if certain milestones are met.